Topic: Health Care
Exploiting Regulatory Loophole Speeds Cancer Drug Development
Pharma companies seek OK for limited use, then expand sales through off-label prescribing, saving millions
How Medical Device Makers Reacted to Publication of a Once-Secret Database of Millions of Adverse Events
New product filings to FDA included stronger safety features and larger technological advances
Out of the Blue, a Colon Cancer Screening Kit Arrives
That approach, closer to an opt-out, beat three nudges, or opt-ins at encouraging younger people to get tested
A Major Medical Center Gets a Cheaper, Fairer Way to Assign Doctors
Model tells schedulers which anesthesiologists should be on call or on-site at specific times
Medicare’s Money-Saving Treatment Caps Leave Some Patients Behind
Paperwork issues at physical therapy providers curtail care more often for minority and low-income patients
A Psychological Approach to Helping Doctors Do Better at Doing No Harm
Behavioral nudges reduced doctors’ overprescribing and overtesting of older patients
Should the U.S. Aim for a Zero-COVID-19 Policy?
Tolerating a low level of transmission just might be the better strategy
$52.6 Billion: Extra Cost to Consumers of Add-On Drug Patents
The figure is a subset, not covering huge expense of extended patents on high-priced biologics like Humira
Anticipating Overcrowding Risk in the ICU
A model vastly outperforms predictions based on prior hospital data
Nursing Home Industry Profits Obscured by Related-Party Transactions
Management and real estate deals to owners’ firms siphon off most profits
The Case for Field Experiments in Behavioral Research
Nudges already proven to work in the real-world increased uptake of COVID-19 boosters; nudges based on lab findings and expert insights, not so much
A Supportive Letter to Doctors on Best Practices Reduces Opioid Prescriptions
In LA, doctors who lose a patient to opioid overdose get a letter from the coroner; tweaking that letter had a substantial impact
When Medicare Pays, Drug Companies Employ Older Subjects in Clinical Trials
The shift lends credibility to medicines vs. trials that exclude people 65 and older
Was Research — on Physicians and Noncompete Agreements — Before Its Time?
Years after a paper goes unpublished, it’s fodder for a major Federal Trade Commission proposal
Huge Spending — But Little Sharing of Research Results — on Cancer Drugs
U.S. efforts to encourage transparency widely ignored by companies
A Nudge to Reduce the Government Tab for Nursing Home Care
An upfront fee for taking Medicaid patients could shorten stays